Boehringer follows Sanofi with job cuts in FranceBoehringer Ingelheim has confirmed it plans to axe more than 10% of its workforce in France, or more Share XBoehringer follows Sanofi with job cuts in Francehttps://pharmaphorum.com/news/boehringer-follows-sanofi-with-job-cuts-in-france/
Amgen cuts US price of cholesterol drug by 60%Amgen is cutting the US price of its cholesterol drug Repatha by 60%, following a similar decision by Share XAmgen cuts US price of cholesterol drug by 60%https://pharmaphorum.com/news/amgen-cuts-us-price-of-cholesterol-drug-by-60/
FDA approves Sanofi/Regeneron’s Dupixent in asthmaThe US regulator has approved Sanofi/Regeneron’s Dupixent (dupilumab) in a new asthma indication, a key step in the Share XFDA approves Sanofi/Regeneron’s Dupixent in asthmahttps://pharmaphorum.com/news/fda-approves-sanofi-regenerons-dupixent-in-asthma/
Sanofi/Regeneron’s Dupixent could be first biologic approved for nasal polypsTrials of Sanofi and Regeneron’s drug Dupixent (dupilumab) have shown positive results for treating patients suffering from chronic Share XSanofi/Regeneron’s Dupixent could be first biologic approved for nasal polypshttps://pharmaphorum.com/news/sanofi-regenerons-dupixent-could-be-first-biologic-approved-for-nasal-polyps/
Novo to market ‘connected’ insulin pens next yearNovo Nordisk is to launch “connected” insulin pens, responding for demands from patients for devices able to communicate Share XNovo to market ‘connected’ insulin pens next yearhttps://pharmaphorum.com/news/novo-to-market-connected-insulin-pens-next-year/
Sanofi to continue with cost-cutting as new drugs show promiseSanofi is to push on with cost-cutting after reaching a target of 1.5 billion euros a year ahead Share XSanofi to continue with cost-cutting as new drugs show promisehttps://pharmaphorum.com/news/sanofi-to-continue-with-cost-cutting-as-new-drugs-show-promise/
Sanofi unveils eczema drug data, as regulators mull label expansionSanofi has revealed details of research, which forms the basis of filings to extend the use of its eczema Share XSanofi unveils eczema drug data, as regulators mull label expansionhttps://pharmaphorum.com/news/sanofi-unveils-eczema-drug-data-as-regulators-mull-label-expansion/
Sanofi to pay $25 million in bribery charges settlementFrench pharma giant Sanofi reached a civil settlement with the US Securities and Exchange Commission (SEC) and agreed Share XSanofi to pay $25 million in bribery charges settlementhttps://pharmaphorum.com/news/sanofi-pays-25-m-bribery-settlement/
Sanofi’s rare disease drug Cablivi approved in the EUThe European Commission has approved Sanofi’s Cablivi, the first treatment for patients with the rare blood-clotting disorder, acquired Share XSanofi’s rare disease drug Cablivi approved in the EUhttps://pharmaphorum.com/news/sanofi-cablivi-approved-europe/
